Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells

Procurement Inclusion Criteria:

Referred patients will initially be consented for procurement of blood for generation of the transduced ATL. Eligibility criteria at this stage include:

1. Diagnosis of recurrent or refractory T-cell acute lymphoblastic leukemia (T-ALL),T-cell acute lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin lymphoma (T-NHL,including Angioimmunoblastic T-cell lymphoma (AITL), Enteropathy-associated T-celllymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL),Peripheral T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), AdultT-cell leukemia/lymphoma, T cell prolymphocytic leukemia with symptomatic disease,Extranodal NK/T cell lymphoma, Mycosis fungoides/ Sezary Syndrome Stage IIB orhigher) or other cutaneous T-cell lymphomas

AND

1. suitable for allogeneic hematopoietic stem cell transplant (HSCT)

2. with a suitable donor identified by a FACT accredited transplant center

3. willing to proceed to transplant if the CD7.CAR treatment induces complete remissionand the patient/donor remain suitable candidates

Using NMDP donor assessment criteria, suitability is defined as "during the search process, a donor is medically fit to proceed to the next step- whether high-resolution or confirmatory HLA testing OR donor work-up." Documentation of suitability (including above criteria) will be confirmed by the investigator prior to treatment.

• For T-NHL subjects, eligibility will be confined to disease stages where allogeneicHSCT is indicated.

2. CD7-positive tumor (≥20% CD7 positive blasts by flow cytometry orimmunohistochemistry (tissue) assessed by a CLIA certified FlowCytometry/Pathology laboratory).

3. Age </=75 years old.. NOTE: The first three (3) patients treated on the studymust be adults (>/=18 yrs of age).

4. Hgb ≥ 7.0 (can be transfused)

5. Life expectancy greater than 12 weeks

6. If pheresis required to collect blood:

• Cr < 1.5 upper limit normal

• AST < 5 × upper limit normal

• PT and APTT <1.5 × upper limit normal

7. Informed consent explained to, understood by and signed bypatient/guardian. Patient/guardian given copy of informed consent.

Procurement Exclusion Criteria:

1. Active infection requiring antibiotics.

2. Active infection with HIV

3. History of other cancer (except non-melanoma skin cancer or in situ breast cancer orcervix cancer) unless the tumor was successfully treated with curative intent atleast 2 years before trial entry.

Treatment Inclusion Criteria:

1. Diagnosis of recurrent or refractory T-cell acute lymphoblastic leukemia (T-ALL),T-cell acute lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin lymphoma (T-NHL, including Angioimmunoblastic T-cell lymphoma (AITL), Enteropathy-associatedT-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Peripheral T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia/lymphoma, T cell prolymphocytic leukemia withsymptomatic disease, Extranodal NK/T cell lymphoma, Mycosis fungoides/ SezarySyndrome Stage IIB or higher) or other cutaneous T-cell lymphomas

AND

1. suitable for allogeneic hematopoietic stem cell transplant (HSCT) 2) with a suitabledonor identified by a FACT accredited transplant center 3) willing to proceed totransplant if the CD7.CAR treatment induces complete remission and the patient/donorremain suitable candidates

Using NMDP donor assessment criteria, suitability is defined as "during the search process, a donor is medically fit to proceed to the next step- whether high-resolution or confirmatory HLA testing OR donor work-up." Documentation of suitability (including above criteria) will be confirmed by the investigator prior to treatment.

• For T-NHL subjects, eligibility will be confined to disease stages where allogeneicHSCT is indicated.

2. CD7-positive tumor (≥20% CD7+ blasts by flow cytometry or immunohistochemistry (tissue) assessed in a CLIA certified Flow Cytometry/Pathology laboratory.

3. Age </=75 years old. NOTE: The first three (3) patients treated on the studymust be adults (>/=18 yrs of age).

4. Bilirubin less than 3 times the upper limit of normal.

5. AST less than 5 times the upper limit of normal.

6. Estimated GFR ≥ 50 mL/min.

7. Pulse oximetry of > 90% on room air

8. Karnofsky or Lansky score of ≥ 60.

9. Recovered from acute toxic effects of prior chemotherapy at least one weekbefore entering this study.

10. Sexually active patients must be willing to utilize one of the more effectivebirth control methods during the study and for 6 months after the study isconcluded. The male partner should use a condom.

11. Informed consent explained to, understood by, and signed by patient/guardian.Patient/guardian given copy of informed consent.

Treatment Exclusion Criteria:

1. Currently receiving any investigational agents or having received any tumor vaccineswithin the previous 6 weeks.

2. History of hypersensitivity reactions to murine protein-containing products.

3. Pregnant or lactating.

4. Tumor in a location where enlargement could cause airway obstruction (perinvestigator discretion).

5. Clinically significant viral infection or uncontrolled viral reactivation of EBV,CMV, Adv, BK-virus, or HHV-6.

6. Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardialinfarction within the last 12 months; Prolonged QT syndrome or secondary prolongedQT, per investigator discretion. Cardiac echocardiography with LVSF<30% or LVEF<50%;or clinically significant pericardial effusion. Cardiac dysfunction NYHA III or IV (Confirmation of absence of these conditions on echocardiogram within 12 months oftreatment).

7. CNS abnormalities: Presence of CNS-3 disease defined as detectable cerebrospinalblast cells in a sample of CSF with ≥ 5 WBCs per mm3 (unless negative by theSteinherz/Bleyer algorithm); Presence of any CNS disorder such as an uncontrolledseizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease,or any autoimmune disease with CNS involvement.